FOR RESEARCH USE ONLY
Early human researchPerformance research

Ipamorelin

Selective ghrelin/GHS-R1a agonist researched for clean pulsatile GH release with minimal cortisol or prolactin impact.

01GHS-R1a02GH release03Pituitary signalling
Molecular signature / ipamorelin
Structural identity

Synthetic pentapeptide GHS-R1a agonist

Also known as

NNC 26-0161 · Selective growth hormone secretagogue

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHRP) that mimics ghrelin's action at the GHS-R1a receptor. It is widely regarded as the cleanest GHRP class member due to its lack of meaningful cortisol, prolactin or aldosterone elevation — a profile that distinguishes it from GHRP-2 and GHRP-6.

The research question

Ipamorelin is notable for receptor selectivity within the growth-hormone secretagogue class. Research commonly compares pulse amplitude with effects on cortisol, prolactin and appetite to separate growth-hormone signalling from less selective secretagogue activity.

Section 02

Mechanism & research themes

Selective agonism of the ghrelin/GHS-R1a receptor on pituitary somatotrophs, triggering acute pulsatile GH release. Frequently stacked with a GHRH analogue (e.g. CJC-1295, Sermorelin, Tesamorelin) for synergistic pulse amplitude.

01

Clean pulsatile GH release without cortisol or prolactin elevation

02

Improved sleep quality, particularly slow-wave architecture

03

Improved body composition (lean mass support, adipose reduction)

04

Enhanced recovery and collagen turnover via downstream IGF-1

05

Synergistic potential when stacked with a GHRH analogue

06

Preserves natural pulsatile GH rhythm without HGH-style axis suppression

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Early human pharmacology and clinical studies exist, but the broader recovery and body-composition narrative relies heavily on extrapolation from the growth-hormone axis.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 100–300mcg subcutaneously 1–3× daily — typically pre-sleep, post-workout and/or fasted morning — to align with natural GH pulse windows. Cycles run 8–12 weeks on / 4 weeks off.

Reported persistence

approximately 2 hours.

Calculator starting point

0.2 mg per reference dose

7 doses per week · 8-week cycle

2 mL default reconstitution volume

100–300 mcg per injection, often 1–3×/day; here defaulted to once daily pre-sleep.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Ipamorelin
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2.5mL bacteriostatic water for a 2,000mcg/mL working concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C (stable up to 24 months frozen). Reconstituted: 2–8°C, protect from light, use within 28–30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Mild water retention and injection-site reactions possible at higher doses.

L2

Best effects typically require GHRH pairing; standalone use produces a smaller GH pulse.

L3

Chronic IGF-1 elevation should be monitored; avoid sustained supraphysiological dosing.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only